Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PREP | P48147 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1631397 | 0.90 | — | — | |
| SCHEMBL1694458 | 0.90 | — | — | |
| SCHEMBL7904677 | 0.90 | CA14 (0.41) | DPP4THRBDPP7CA14SMN1; SMN2 | |
| SCHEMBL1631394 | 0.90 | — | — | |
| Hydrochloric Acid SCHEMBL3838599 | 0.88 | CA14 (0.40) | DPP4THRBCA14SMN1; SMN2ALOX5 | |
| Hydrochloric Acid SCHEMBL17389174 | 0.88 | CA14 (0.40) | DPP4THRBCA14SMN1; SMN2ALOX5 | |
| SCHEMBL15974641 | 0.82 | POLB (0.40) | THRBCA14SMN1; SMN2ALOX5SLC6A3 | |
| SCHEMBL8238357 | 0.82 | SLC6A3 (0.36) | DPP4THRBKCNH2CA14SMN1; SMN2 | |
| SCHEMBL21579732 | 0.82 | DPP4 (0.41) | DPP4THRBDPP7CA14SMN1; SMN2 | |
| SCHEMBL13209988 | 0.82 | DPP4 (0.41) | DPP4THRBDPP7CA14SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030171400-A1 | Heterocyclic side chain containing metalloprotease inhibitors | PROCTER & GAMBLE COMPANY, THE | 2003-09-11 | — | — | US | disclosed |
| EP-1265863-A1 | HETEROCYCLIC SIDE CHAIN CONTAINING METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001070690-A1 | HETEROCYCLIC SIDE CHAIN CONTAINING METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171400-A1 | Heterocyclic side chain containing metalloprotease inhibitors | SERPINB1, ADAM17, TMPRSS15 | DPP4 121/4885THRB 3133/4885DPP7 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.